Prostate cancer: therapeutic patent review

Bibliography

• LANDIS SH, MURRAY T, BOLDEN S et al: Cancer statis-tics, 1999. CA Cancel". Clin. (1999) 49(1):8–31.
   Google Scholar
• KAMOI K, BABAIAN RJ: Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer. Semin. Oncol. (1999) 26(2):140–149.
   PubMedGoogle Scholar
• AUCLERC G, ANTOINE EC, CAJFINGER F et al.: Manage-ment of advanced prostate cancer. Oncologist (2000) 5 (1):36–44.
   PubMedGoogle Scholar
• HEGARTY NJ, FITZPATRICK JM, RICHIE JP et al.: Future prospects in prostate cancer. Prostate (1999) 40 (4): 261–268.
   PubMedGoogle Scholar
• CRAWFORD ED, BENNETT CL, STONE NN et al.: Comparison of perspectives on prostate cancer: analyses of survey data. Urology (1997) 50(3):366–372.
   PubMedGoogle Scholar
• KUNKEL EJ, BAKKER JR, MYERS RE et al.: Biopsychoso-cial aspects of prostate cancer. Psychosomatics (2000) 41 (2):85–94.
   PubMed Web of Science ®Google Scholar
• CARLIN B, ANDRIOLE GL: The natural history, skeletal complications and management of bone metastases in patients with prostate carcinoma. Cancer (2000) 88 (12)Suppl.:2989–2994.
   Google Scholar
• PORTER AT, MCEWAN AJ, POWE JE et al.: Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int. j RadiaL Oncol. Biol. Phys. (1993) 25(5):805–813.
   Google Scholar
• SERAFINI AN: Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer (2000) 88 (12)Suppl.:2934–2939.
   Google Scholar
• ROGERS MJ, GORDON S, BENFORD HL etal.: Cellular and molecular mechanisms of action of bisphosphonates. Cancer (2000) 88 (12)Suppl.:2961–2978.
   Google Scholar
• PAPAPOULOS SE, HAMDY NAVAN DER, PLUIJM G: Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton. Cancer (2000) 88 (12)Suppl.:3047–3053.
   Google Scholar
• PATERSON AH: The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases. Cancer (2000) 88 (12)Suppl.:3038–3046.
   Google Scholar
• LUKE M, COFFEY D: The Physiology of Reproduction. Knobil E, Neill J (Eds.), (1994):1435–1487.
   Google Scholar
• ISAACS JT: Apoptosis: translating theory to therapy for prostate cancer. J Natl. Cancer Inst. (2000) 92 (17):1367–1369.
   PubMedGoogle Scholar
• SADAR MD, HUSSAIN M, BRUCHOVSKY N: Prostate cancer: molecular biology of early progression to androgen independence. Endocr. RelaL Cancer (1999) 6 (4):487–502.
   PubMed Web of Science ®Google Scholar
• LABRIE F, BELANGER A, DUPONT A et al.: Science behind total androgen blockade: from gene to combination therapy. Clin. Invest. Med. (1993) 16(6):475–492.
   PubMedGoogle Scholar
• HUGGINS C, HODGES CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin. (1972) 22(0232–240.
   Google Scholar
• STRUM SB, SCHOLZ MC, MCDERMED JE: Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. Oncologist (2000) 5 (1):45–52.
   PubMedGoogle Scholar
• KLOTZ L: Hormone therapy for patients with prostate carcinoma. Cancer (2000) 88 (12)Suppl.:3009–3014.
   Google Scholar
• GARNICK MB: Hormonal therapy in the management of prostate cancer: an historical overview. Mai. Urol. (1999) 3(3):175–182.
   PubMedGoogle Scholar
• STUDER UE MILLS RD: Arguments against the long-term use of combined androgen blockade. Eur. Urol. (1998) 34 (Suppl. 3):29–32.
   Google Scholar
• GRANFORS T, MODIG H, DAMBER JE et al.: Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J. Urol. (1998) 159 (6):2030–2034.
   PubMedGoogle Scholar
• MESSING EM, MANOLA J, SAROSDY M et al.: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl. J. Med. (1999) 341 (201781–1788.
   Google Scholar
• SAROSDY MF, SCHELLHAMMER PF, JOHNSON R et al.: Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy? Urology (2000) 55(3):391–395. Discus-sion 395–396.
   Google Scholar
• BRATOEFF E, RAMIREZ E, MURILLO E et al.: Steroidal antiandrogens and 5alpha-reductase inhibitors. Curr. Med. Chem (1999) 6(12):1107–1123.
   PubMedGoogle Scholar
• SINGH SM GAUTHIER S LABRIE F: Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr. Med. Chem. (2000) 7 (2) : 211–247.
   PubMedGoogle Scholar
• SEIDENFELD J, SAMSON DJ, HASSELBLAD V et al.: Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann. Intern. Med. (2000) 132 (7) :566–577.
   PubMed Web of Science ®Google Scholar
• SCHALLY AV: Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides (1999) 20(10):1247–1262.
   PubMed Web of Science ®Google Scholar
• EISENBERGER MA, ABRAMS JS: Chemotherapy for prostatic carcinoma. Semin. Urol. (1988) 6(0303–310.
   PubMedGoogle Scholar
• COOK T, SHERIDAN WP: Development of GnItHantago-nists for prostate cancer: new approaches to treatment. Oncologist (2000) 5 (2) :162–168.
   PubMedGoogle Scholar
• COMARU-SCHALLY AM, BRANNAN W, SCHALLY AV et al.: Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. (1998) 83 (11):3826–3831.
   PubMedGoogle Scholar
• LJUNGQVIST A, FENG DM, HOOK W et al.: An tide and related antagonists of luteinizing hormone release with long action and oral activity. Proc. Nati Acad. Sci. USA (1988) 85(20:8236–8240.
   PubMedGoogle Scholar
• JANECKA A, JANECKI T, BOWERS CY et al.: New, highly active antagonists of LIIRII with acylated lysine and p-aminophenylalanine in positions 5 and 6. Intl PepL Protein Res. (1994) 44(0:19–23.
   PubMedGoogle Scholar
• REISSMANN T, SCHALLY AV, BOUCHARD P et al.: The LIIRII antagonist cetrorelix: a review. Hum. Reprod. Update (2000) 6(4):322–331.
   PubMedGoogle Scholar
• MCLEOD D, ZINNER N, GLEASON D et al.: Abar elix -dep ot (A-D) versusleuprolide acetate (L) for prostate cancer: results of a multi-institutional, randomized, Phase III study in 271 patients. Proc. ASCO (2000) 2000:1306a.
   Google Scholar
• EMONS G, MULLER V, ORTMANN O et al.: Effects of LIABH-analogues on mitogenic signal transduction in cancer cells. J. Steroid Biochem. Moi Biol. (1998) 65 (1-6):199–206.
   PubMedGoogle Scholar
• MARELLI MM, MORETTI RM, DONDI D et al.: luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells. Endocrinology (1999) 140(1) :329–334.
   PubMedGoogle Scholar
• RIVIER JE, PORTER J, RIVIER CL et al.: New effective gonadotropin releasing hormone antagonists with minimal potency for histamine release in vitro. I Med. Chem (1986) 20 (10) :1846–1851.
   Google Scholar
• SCHER HI, MAZUMDAR M, KELLY WK: Clinical trials inrelapsed prostate cancer: defining the target. J. Nati Cancer Inst. (1996) 88(22):1623–1634.
   PubMedGoogle Scholar
• SMALL EJ, VOGELZANG NJ: Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J. Clin. Oncol. (1997) 15(0:382–388.
   PubMedGoogle Scholar
• KELLY WK, SCHER HI: Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome./ Urol. (1993) 149(3):607–609.
   PubMed Web of Science ®Google Scholar
• KELLY WK, SLOVIN S, SCHER HI: Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urol. Clin. North Am. (1997) 24 (2):421–431.
   PubMedGoogle Scholar
• SCHER HI, KELLY WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol. (1993) 11 (8):1566–1572.
   PubMed Web of Science ®Google Scholar
• SCHER HI, ZHANG ZF, NANUS D et al: Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology (1996) 47 (1A)Suppl.:61–69.
   Google Scholar
• SCHER HI, KOLVENBAG GJ: The antiandrogen withdrawal syndrome in relapsed prostate cancer. Eur. Urol. (1997) 31 (Suppl. 2):3–7. Discussion 24–27.
   Google Scholar
• JENSTER G: The role of the androgen receptor in the development and progression of prostate cancer. Semin. Oncol. (1999) 2 6 (4) :407–421.
   Google Scholar
• NAM RK, ELHAJI Y, KRAHN MD et al: Significance of the cag repeat polymorphism of the androgen receptor gene in prostate cancer progression Rn Process Citation]. J. Urol. (2000) 1 6 4 (2) : 567–572.
   Google Scholar
• JENSTER G: Ligand-independent activation of the androgen receptor in prostate cancer by growth factors and cytokines. j Pathol. (2000) 191 (3):227–228.
   PubMed Web of Science ®Google Scholar
• ZHAO XY, MALLOY PJ, KRISHNAN AV et al: Glucocorti-coids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med. (2000) 6(6):703–706.
   PubMed Web of Science ®Google Scholar
• MIYOSHI Y, UEMURA H, FUJINAMI K et al.: Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromo-somal anomalies in prostate cancer in Japanese patients. Prostate (2000) 43(3):225–232.
   PubMedGoogle Scholar
• CHEN T, WANG LH, FARRAR WL: Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcrip-tion 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res. (2000) 60 (8) :2132–2135.
   PubMed Web of Science ®Google Scholar
• SADAR MD, HUSSAIN M, BRUCHOVSKY N: Prostate cancer: molecular biology of early progression to androgen independence. Endocr. Relat. Cancer (1999) 6 (4):487–502.
   PubMed Web of Science ®Google Scholar
• WALLEN MJ, LINJA M, KAARTINEN K et al.: Androgen receptor gene mutations in hormone-refractory prostate cancer. J. Pathol (1999) 189 (0559–563.
   PubMed Web of Science ®Google Scholar
• YAGODA A, PETRYLAK D: Cyto to x ic chemotherapy for advanced hormone-resistant prostate cancer. Cancer (1993) 71 (3)Suppl.:1098–1109.
   Google Scholar
• SCHER HI, HELLER G: Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology (2000) 55(3):323–327.
   PubMed Web of Science ®Google Scholar
• FAZZARI M, HELLER GS, CHER HI: The Phase II/HI transi-tion. Toward the proof of efficacy in cancer clinical trials. Control. Clin. Trials (2000) 21 (0360–368.
   PubMedGoogle Scholar
• OH WK: Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy. Cancer (2000) 88 (12)Suppl.:3015–3021.
   Google Scholar
• KANTOFF PW, HALABI S, CONAWAY Metal.: Hydrocorti-sone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin. Oncol (1999) 17 (8):2506–13.
   Google Scholar
• TANNOCK IF: Treatment of cancer with radiation and drugs. J. Clin. Oncol. (1996) 14(12):3156–3174.
   PubMed Web of Science ®Google Scholar
• PHILLIPS KA, TANNOCK IF: Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J. Clin. Oncol. (1998) 16(03179–3190.
   PubMedGoogle Scholar
• SWEAT SD, PACELLI A, MURPHY GP et al.: Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology (1998) 5 2 (0637–640.
   Google Scholar
• CHANG SS, GAUDIN PB, REUTER VE et al.: Prostate-specific membrane antigen: much more than a prostate cancer marker. Mol. Urol. (1999) 3(3):313–320.
   PubMedGoogle Scholar
• ELGAMAL AA, HOLMES EH, SU SL et al: Prostate-specific membrane antigen (PSMA): current benefits and future value. Semin. Surg. Oncol (2000) 1 8 (1):10–16.
   Google Scholar
• GONG MC, CHANG SS, SADELAIN M et al.: Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metastasis Rev. (1999) 18(4)483–490.
   Google Scholar
• CHANG SS, O'KEEFE DS, BACICH DJ et al.: Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin. Cancer Res. (1999) 5 (10):2674–2681.
   Google Scholar
• CHANG SS, REUTER VE, HESTON WD etal.: Five differentanti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. (1999) 59 (13):3192–3198.
   Google Scholar
• LIU H MOY P, KIM S et al.: Monoclonal antibodies to theextracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. (1997) 57 (17):3629–3634.
   Google Scholar
• DENMEADE SR, ISAACS JT: Enzymatic activation ofprodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer. Cancer I ScL Am. (1998) 4 (Suppl. 1):S15–21.
   Google Scholar
• CHAN JM, STAMPFER MJ, GIOVANNUCCI E et al.: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (1998) 279(5350563–566.
   Google Scholar
• DJAVAN B, BURSA B, SEITZ C et al.: Insulin-like growth factor 1 (IGF-1), IGF-1 density and IGF-1/PSA ratio for prostate cancer detection. Urology (1999) 54(4)603–606.
   Google Scholar
• SUTKOWSKI DM, GOODE RL, BANIEL J et al.: Growth regulation of prostatic stromal cells by prostate-specific antigen. J. Natl. Cancer Inst. (1999) 91 (19):1663–1669.
   PubMedGoogle Scholar
• SLOVIN SF, SCHER HI: Rising PSAs after primary therapy: active or passive intervention. Semin. Urol. Oncol. (1999) 17(3):164–173.
   PubMedGoogle Scholar
• SLOVIN SF RAGUPATHI G ADLURI S et al.: Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo Hhexasaccharide conjugate in man. Proc. NatI Acad. Sci. USA (1999) 96(10):5710–575.
   PubMedGoogle Scholar
• MURPHY GP, TJOA BA, SIMMONS SJ et al: Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate (2000) 43 (1):59–62.
   PubMedGoogle Scholar
• VIEWEG J: The evolving role ofdendritic cell therapy in urologic oncology. Curr. Opin. Urol. (2000) 10(0307–312.
   PubMedGoogle Scholar